Triplet therapy including belamaf prolongs survival in multiple myeloma
by Elana GotkineFor patients with relapsed or refractory multiple myeloma (RRMM), triplet therapy of belantamab mafodotin (belamaf) plus bortezomib and dexamethasone (BVd) improves outcomes, with an a
Updated on: March 24,2024
Triplet therapy including belamaf prolongs survival in multiple myeloma
by Elana GotkineFor patients with relapsed or refractory multiple myeloma (RRMM), triplet therapy of belantamab mafodotin (belamaf) plus bortezomib and dexamethasone (BVd) improves outcomes, with an a
Updated on:March 24,2024
